

What is claimed is:

1. A composition comprising at least two immunogenic ligands, wherein said  
5 immunogenic ligands are individually characterized by an ability to elicit an  
immune response against the same native ligand, and wherein said immunogenic  
ligand is selected from the group consisting of LSGIGILTV (SEQ ID NO:3),  
LTGIGILTV (SEQ ID NO:5), VTGIGILTV (SEQ ID NO:7), FAGIGILTV (SEQ  
ID NO: 9), TAGIGILTV (SEQ ID NO 11), GVGIGILTV (SEQ ID NO 13),  
10 FLFHTEYVV (SEQ. ID NO. 15), FLFHTAYIV (SEQ. ID NO. 17),  
FLYHTPMVV (SEQ ID NO. 19); FLYHTPMIV (SEQ ID NO. 21),  
FLTPLGPRV (SEQ ID NO. 23) and AAGIGILTV (SEQ ID NO:25)
2. The composition of claim 1, further comprising a carrier.
3. The composition of claim 2, wherein the carrier is a pharmaceutically acceptable  
15 carrier.
4. A host cell comprising at least two immunogenic ligands, wherein said  
immunogenic ligands are individually characterized by an ability to elicit an  
immune response against the same native ligand, and wherein said immunogenic  
ligand is selected from the group consisting of LSGIGILTV (SEQ ID NO:3),  
20 LTGIGILTV (SEQ ID NO:5), VTGIGILTV (SEQ ID NO:7), FAGIGILTV (SEQ  
ID NO: 9), TAGIGILTV (SEQ ID NO 11), GVGIGILTV (SEQ ID NO 13),  
FLFHTEYVV (SEQ. ID NO. 15), FLFHTAYIV (SEQ. ID NO. 17),  
FLYHTPMVV (SEQ ID NO. 19); FLYHTPMIV (SEQ ID NO. 21),  
FLTPLGPRV (SEQ ID NO. 23) and AAGIGILTV (SEQ ID NO:25)
5. The host cell of claim 4, wherein the host cell is an antigen presenting cell and  
25 the immunogenic ligands are presented on the surface of the cell.
6. The host cell of claim 5, wherein the antigen presenting cell is a dendritic cell.
7. A composition comprising the host cell of any of claims 4 to 6 and a carrier.

8. The composition of claim 7, wherein the carrier is a pharmaceutically acceptable carrier.
9. A method for inducing an immune response in a subject, comprising delivering to the subject a composition comprising an effective amount of two or more immunogenic ligands, wherein each of said immunogenic ligands is characterized by an ability to elicit an immune response against the same native ligand, and wherein said immunogenic ligand is selected from the group consisting of LSGIGILTV (SEQ ID NO:3), LTGIGILTV (SEQ ID NO:5), VTGIGILTV (SEQ ID NO:7), FAGIGILTV (SEQ ID NO: 9), TAGIGILTV (SEQ ID NO 11), GVGIGILTV (SEQ ID NO 13), FLFHTEYVV (SEQ. ID NO. 15), FLFHTAYIV (SEQ. ID NO. 17), FLYHTPMVV (SEQ ID NO. 19); FLYHTPMIV (SEQ ID NO. 21), FLTPLGPRV (SEQ ID NO. 23) and AAGIGILTV (SEQ ID NO:25).